News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Astellas Pharma Inc. Withdraws Japan Filing for Darexaban, Looks for Partners
February 16, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Pharma Times -- Astellas Pharma has pulled its filing in Japan for its oral Factor Xa inhibitor darexaban after regulators said they needed to see more data.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Astellas Pharma US, Inc.
MORE ON THIS TOPIC
Regulatory
Future of Aardvark’s Prader-Willi drug in doubt as FDA slaps full hold on program
May 15, 2026
·
2 min read
·
Tristan Manalac
FDA
Biotech leaders pitch Pazdur as next FDA chief
May 14, 2026
·
2 min read
·
Annalee Armstrong
Approvals
BeOne wins mantle cell lymphoma approval, opening new therapy class
May 14, 2026
·
2 min read
·
Tristan Manalac
Complete response letters
UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged
May 13, 2026
·
3 min read
·
Annalee Armstrong
